New treatment for opioid use disorder using a specific receptor blocker
NOP Receptor Antagonist for OUD Pharmacotherapy
This study is testing a new medication called BTRX-246040 to see if it can help people with opioid use disorder by reducing their cravings for oxycodone while keeping them safe, and it’s designed for those looking to improve their recovery with some extra support.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10085851 on NIH RePORTER |
What this research studies
This research investigates a novel medication designed to help individuals struggling with opioid use disorder (OUD) by blocking a specific receptor in the brain that is involved in opioid addiction. The study will evaluate the effectiveness of a selective nociceptin receptor antagonist, BTRX-246040, in reducing the intake of oxycodone without causing abuse. Participants will be monitored for their response to the medication, which aims to improve recovery outcomes when combined with psychosocial support. The research is conducted through early-stage clinical trials to assess safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with opioid use disorder who are seeking treatment options.
Not a fit: Patients who are not struggling with opioid use disorder or those who are currently using other forms of medication-assisted treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with opioid use disorder, potentially reducing their reliance on opioids and improving recovery rates.
How similar studies have performed: While the specific approach of using a nociceptin receptor antagonist for OUD is novel, similar strategies targeting receptor functions have shown promise in other addiction treatments.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Cunningham, Kathryn a. — University of Texas Med Br Galveston
- Study coordinator: Cunningham, Kathryn a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.